Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Olema Oncology

< Previous 1 2 Next >
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology to Participate in Upcoming Investor Conferences in June
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Olema Oncology
Via GlobeNewswire
Tickers OLMA
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.